He said the question of vaccinating the public was one of balancing “risk and benefit”, pointing to factors such as cost and potential side effects. Currently large-scale vaccination is not required at this stage – although this may change if a more severe outbreak occurs, Gao said.
The policy also identifies China in addition to several Western governments, specifically Australia, with plans to launch a mass public vaccination campaign.
The number of reported viruses from China has remained low since spring. There have been some flashes in northeastern Jilin province in May, its outbreak in Beijing in June and another incident in Xinjiang, the capital of Urumqi in July – but these were subjected to immediate lockdown measures and large-scale trials. And the outbreak was contained within a few weeks.
Gao cited these brief outbreaks as evidence of China’s effective control measures. According to the China News Service, “facts have proved that we have many magical weapons to respond to the epidemic.”
Any potential vaccine would be preferred for those in the front lines, he said: medical staff, Chinese citizens working abroad in virus hostpots, and dense, high-risk environments such as restaurants, schools or sanitation People working in services.
CNN reached out to NHC for further comment.
Global race for vaccine
China is the world’s largest producer and consumer of the vaccine, and according to the 2018-2022 China Human Vaccine Industry Report, can supply more than 1 billion doses annually from 40 manufacturers across the country.
Nine out of more than 30 vaccines currently in human trials globally are from China – the most from any country. And four of the nine vaccine candidates in late-stage trials are being developed by Chinese companies.
Other countries may follow suit; The Indian Health Minister said on Sunday that the government was considering giving emergency authorization to Kovid-19 vaccine candidates before the completion of Phase 3 trials.
Experts have previously stated that vaccination is important for countries such as China, where the percentage of infected people within the population is relatively low due to strict prevention measures.
But Gao warned on Saturday that vaccine development is still in progress, with the risk of poor growth.
“Since no Kovid-19 vaccine has ever been developed before, making this case much earlier in science, it is possible that it may induce ADE (antibody-dependent enhancement) effects as any other first. We will possibly cope. ” Said, according to the Global Times.
ADE occurs when specific antibodies help a virus to enter and replicate cells – basically, when a treatment makes the disease worse.
“Scientific research is a very rigorous process, we need to give scientists a little more time,” he said.